Trial
NCT03319316
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Squamous Non-small Cell Lung Cancer
Intervention
Durvalumab
Why stopped
Interest withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-10